Journal: Clinical Cancer Research

Article Title: Subsets of Very Low Risk Wilms Tumor Show Distinctive Gene Expression, Histologic, and Clinical Features

doi: 10.1158/1078-0432.ccr-09-0312

Figure Lengend Snippet: Fig. 3. Immunohistochemistochemical validation of protein expression in VLRWT. A, immunohistochemical analysis for HMGA2. All 4 C1 tumors were negative (left); all 7 tumors within C2 were immunoreactive for HMGA2 in >10% of the cells. B, immunohistochemical analysis for PDGFRA. All 4 C1 tumors showed immunoreactivity in <10% of cells (left); of 7 C2 tumors, <10% of the cells were immunoreactive in 3 tumors and >10% of the cells were immunoreactive in 4 tumors (right). C, immunohistochemical analysis for WT1. All 4 C1 tumors were immunoreactive for WT1 in >10% of the cells (left); of 7 C2 tumors, 5 showed <10% of the cells to be positive and 2 showed >10% of the cells positive (right). D, immunohistochemical analysis for PAX8. All 4 C1 tumors showed >80% of the cells to be immunoreactive for PAX8; of 6 evaluable C2 tumors, all showed >10% of the cells to be immunoreactive (right).

Article Snippet: The following monoclonal antibodies were tested: WT1 (DAKO; dilution 1:75), PAX8 (ProteinTech Group; dilution 1:100), PDGFRA (Lab Vision; dilution 1:50), and HMGA2 (R&D Systems; dilution 1:750).

Techniques: Biomarker Discovery, Expressing, Immunohistochemical staining

Journal: Cancers

Article Title: Overexpression of Replication-Dependent Histone Signifies a Subset of Dedifferentiated Liposarcoma with Increased Aggressiveness

doi: 10.3390/cancers13133122

Figure Lengend Snippet: HMGA2 lay upstream of RD-HIST. ( A ) Identification of TFs showing a strong correlation with RD-HIST and DD-specific somatic amplification, leading to two candidates. ( B ) Correlation distribution of TFs against histone subtypes. ( C ) DD-specific somatic amplification involving the two candidate TFs, namely, HMGA2 and PLRG1 . ( D ) Correlation of HMGA2 against whole genes, displaying histone genes at the top. ( E ) Western blot of HMGA2 and selected histones from tumor samples (up) and various cell lines (bottom). ( F ) Correlation between HMGA2 expression and cell proliferation indices of the tumor samples.

Article Snippet: Each vector expressing HMGA2 (OriGene; RC214681L1), HMGA2 -shRNA (Sigma; SHCLNG-NM_003483), or GFP -shRNA was produced via co-transfection with pMD2.G and psPAX2 into Lenti-X 293T cells (Clonetech).

Techniques: Amplification, Western Blot, Expressing

Journal: Cancers

Article Title: Overexpression of Replication-Dependent Histone Signifies a Subset of Dedifferentiated Liposarcoma with Increased Aggressiveness

doi: 10.3390/cancers13133122

Figure Lengend Snippet: HMGA2 controls RD-HIST expression, LPS cell proliferation, and tumor size. ( A ) Exogenous introduction of HMGA2 in 94T778 cells and difference in cell proliferation measured using MTT assays. ( B ) Western blot of selected histones on LPS246—a DDLPS cell line (left) and colony formation assay (right). ( C ) Knockdown of HMGA2 in LPS863 cells and difference in cell proliferation using MTT assays. ( D ) Western blot of selected histones on LPS863—a DDLPS cell line (left) and colony formation assay (right)—using knockdown of HMGA2 on LPS863 and 18DD cells. ( E ) RT-PCR quantification of cell-cycle genes in LPS863 cells expressing control-shRNA or HMGA2 -shRNA. ( F ) Growth of control and HMGA2 -knockdown cell xenografts in mice. ( G ) Whole-mount images of the xenograft samples in ( F ). Scale bar: 1 cm. ( A , C , E ) Data presented as the mean ± SD from three independent experiments (*, p < 0.005, **, p < 0.05, ***, p < 0.001).

Article Snippet: Each vector expressing HMGA2 (OriGene; RC214681L1), HMGA2 -shRNA (Sigma; SHCLNG-NM_003483), or GFP -shRNA was produced via co-transfection with pMD2.G and psPAX2 into Lenti-X 293T cells (Clonetech).

Techniques: Expressing, Western Blot, Colony Assay, Knockdown, Reverse Transcription Polymerase Chain Reaction, Control, shRNA

Journal: iScience

Article Title: A mechanistic basis for the malignant progression of salivary gland tumors

doi: 10.1016/j.isci.2021.103508

Figure Lengend Snippet: Key resources table

Article Snippet: The following primary antibodies were used: chicken anti-GFP for Rosa-YFP detection (Abcam, ab13970), rabbit anti-E-cadherin (Cell Signaling Technology, 24E10), goat anti-HMGA2 (R&D Systems, AF3184), goat anti-SOX2 (R&D Systems, AF2018), mouse anti-vimentin (IgM, Developmental Studies Hybridoma Bank, 40E-C), and rabbit anti-Active Caspase-3 (R&D Systems, AF835).

Techniques: Recombinant, Imaging, Software